Vistagen Therapeutics (NASDAQ:VTGN) Share Price Passes Above 50 Day Moving Average – Here’s Why

Vistagen Therapeutics, Inc. (NASDAQ:VTGN) shares crossed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $2.84 and traded as high as $2.90. Vistagen Therapeutics shares last traded at $2.87, with a volume of 182,113 shares.

Vistagen Therapeutics Stock Up 0.7 %

The business’s 50 day simple moving average is $2.84 and its two-hundred day simple moving average is $2.98.

Vistagen Therapeutics (NASDAQ:VTGN) last released its quarterly earnings results on Thursday, February 13th. The company reported ($0.46) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.02. The business had revenue of $230 billion during the quarter, compared to the consensus estimate of $0.18 million. Vistagen Therapeutics had a negative return on equity of 48.12% and a negative net margin of 6,777.08%. On average, equities research analysts anticipate that Vistagen Therapeutics, Inc. will post -1.77 EPS for the current fiscal year.

Institutional Investors Weigh In On Vistagen Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Stempoint Capital LP boosted its holdings in Vistagen Therapeutics by 26.1% during the 4th quarter. Stempoint Capital LP now owns 2,328,492 shares of the company’s stock worth $6,869,000 after acquiring an additional 481,700 shares during the last quarter. Nantahala Capital Management LLC lifted its position in shares of Vistagen Therapeutics by 30.6% during the fourth quarter. Nantahala Capital Management LLC now owns 1,981,980 shares of the company’s stock valued at $5,847,000 after purchasing an additional 464,284 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Vistagen Therapeutics by 4,826,425.0% during the fourth quarter. JPMorgan Chase & Co. now owns 772,244 shares of the company’s stock worth $2,278,000 after purchasing an additional 772,228 shares during the last quarter. Almitas Capital LLC bought a new stake in Vistagen Therapeutics in the 4th quarter worth about $751,000. Finally, Two Sigma Investments LP increased its stake in Vistagen Therapeutics by 123.2% in the 4th quarter. Two Sigma Investments LP now owns 137,334 shares of the company’s stock valued at $405,000 after buying an additional 75,792 shares during the last quarter. 78.39% of the stock is owned by hedge funds and other institutional investors.

Vistagen Therapeutics Company Profile

Vistagen Therapeutics, Inc, a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines.